Financial Comparison: PharmaCyte Biotech (OTCMKTS:PMCBD) and Aura Biosciences (NASDAQ:AURA)

Aura Biosciences (NASDAQ:AURA) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Valuation and Earnings

This table compares Aura Biosciences and PharmaCyte Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$76.41 million	($1.73)	-4.49
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Profitability

This table compares Aura Biosciences and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-41.57%	-36.43%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Insider and Institutional Ownership

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Aura Biosciences has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Aura Biosciences and PharmaCyte Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	0	0	5	2	3.29
PharmaCyte Biotech	0	0	0	0	0.00

Aura Biosciences currently has a consensus target price of $23.00, indicating a potential upside of 196.01%. Given Aura Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Aura Biosciences is more favorable than PharmaCyte Biotech.

Summary

Aura Biosciences beats PharmaCyte Biotech on 9 of the 10 factors compared between the two stocks.

About Aura Biosciences

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.